Biocon's Q1 FY 2025-26 Quarterly Results

Result Summary

• Biocon Ltd reported a 1.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.9%.
• Its expenses for the quarter were up by 8.0% QoQ and 13.6% YoY.
• The net profit decreased 60.0% QoQ and decreased 89.6% YoY.
• The earnings per share (EPS) of Biocon Ltd stood at 0.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Biocon Ltd is a leading biopharmaceutical company based in India. The company is known for its focus on biologics, biosimilars, and generic formulations, catering primarily to global markets. Biocon operates within the pharmaceutical and biotechnology industry, and it has been a prominent player in developing affordable healthcare solutions. Although recent major developments specific to Biocon are not provided in the current context, the company continues to emphasize innovation in its product offerings and expansion of its global footprint.

## Revenue
In the first quarter of fiscal year 2026 (Q1FY26), Biocon Ltd reported a total income of ₹4021.60 crores. This represents a quarter-over-quarter (QoQ) increase of 1.4% from ₹3965.70 crores in Q4FY25. However, when compared to the same quarter in the previous fiscal year (Q1FY25), the total income decreased by 11.9% from ₹4567.40 crores. The revenue figures highlight slight growth on a quarterly basis but a more notable decline year-over-year (YoY).

## Profitability
Biocon's profitability metrics for Q1FY26 show a significant decrease compared to previous periods. The profit before tax stood at ₹96.90 crores, marking a 69.9% decline from Q4FY25's ₹321.70 crores and a 91.5% decrease from ₹1145.50 crores in Q1FY25. After accounting for tax expenses, the profit after tax in Q1FY26 was ₹89.20 crores, down by 60.0% QoQ from ₹222.90 crores and by 89.6% YoY from ₹861.80 crores. The earnings per share (EPS) for the quarter was ₹0.30, showing a reduction of 72.7% from Q4FY25's ₹1.10 and a 94.5% decline from ₹5.50 in Q1FY25.

## Operating Metrics
The total expenses for Biocon in Q1FY26 amounted to ₹3924.70 crores, reflecting an 8.0% increase QoQ from ₹3635.20 crores in Q4FY25 and a 13.6% increase YoY from ₹3453.90 crores in Q1FY25. The tax paid in Q1FY26 was ₹7.70 crores, which is a significant reduction of 92.0% from the previous quarter's ₹96.10 crores and a 97.3% decrease from ₹283.70 crores in Q1FY25. These figures indicate that while Biocon's expenses have increased both quarterly and annually, the tax expenses have decreased substantially over the same periods.